Targeting the kinase ataxia–telangiectasia mutated (ATM) in combination with RT has emerged as a promising therapeutic strategy for brain tumors, and may be especially effective for brainstem gliomas harboring TP53 alterations. The gene discussed is TP53; the disease is brain stem glioma.